Today’s webinar was particularly interesting for me, especially...

Today’s webinar was particularly interesting for me, especially Jon’s reply to the question “ has NEU applied for Breakthrough Therapy for 2591?” I can’t answer that. Last time I mentioned BT it didn’t go well.

I’ll take that as a yes, but we’ll have to wait and see. I’ve previously posted my thoughts on this subject. They would be crazy not to have a go. Costs us nothing, A Rare Orphan Drug for children with Fast Track has as good a shot as any.

I still think we’ll see an offer for NEU after the Type C meeting confirms the PH3 Trial Protocols and Endpoints. BIG Pharma and ACAD. can see everything we can see. The proposition that DAYBUE European will likely match North American income , which itself should double over next 2 years, is very exciting, And it also adds incentive for ACAD to take us out..

Looking past the artificially low SP, it’s only a matter of time. The 9 brokers following NEU attest to the leevel of interest in NEU.

Let’s hope the new indications are released by the date of the FDA type C meeting in early April. It’s all happening here except the SP which JON said he is working hard to get momentum back under the shareprice.